Profound Medical Corp. (PROF)
NASDAQ: PROF · Real-Time Price · USD
7.44
-0.06 (-0.80%)
Oct 22, 2024, 4:00 PM EDT - Market closed
Profound Medical Revenue
Profound Medical had revenue of $2.23M in the quarter ending June 30, 2024, with 39.39% growth. This brings the company's revenue in the last twelve months to $7.88M, up 16.67% year-over-year. In the year 2023, Profound Medical had annual revenue of $7.20M with 7.75% growth.
Revenue (ttm)
$7.88M
Revenue Growth
+16.67%
P/S Ratio
n/a
Revenue / Employee
$60,153
Employees
131
Market Cap
183.73M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.20M | 518.00K | 7.75% |
Dec 31, 2022 | 6.68M | -192.00K | -2.79% |
Dec 31, 2021 | 6.87M | -431.00K | -5.90% |
Dec 31, 2020 | 7.30M | 3.13M | 74.99% |
Dec 31, 2019 | 4.17M | 1.57M | 60.40% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nevro | 426.10M |
LifeMD | 178.28M |
Lifecore Biomedical | 128.44M |
Organigram Holdings | 110.30M |
Electromed | 54.72M |
Senseonics Holdings | 24.04M |
Cellectis | 19.64M |
Sangamo Therapeutics | 12.28M |
PROF News
- 5 days ago - Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow - GlobeNewsWire
- 6 days ago - Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer - GlobeNewsWire
- 6 weeks ago - Profound Medical to Participate in Lake Street's Best Ideas Growth Conference - GlobeNewsWire
- 2 months ago - Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow - GlobeNewsWire
- 3 months ago - Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases - GlobeNewsWire
- 5 months ago - Profound Medical Annual General Meeting of Shareholders Voting Results - GlobeNewsWire
- 5 months ago - Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan - GlobeNewsWire